- Home
- ASRT vs IMMX Comparison
ASRT vs IMMX Comparison
Compare ASRT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- IMMX
- Stock Information
- Founded
- ASRT 1995
- IMMX 2014
- Country
- ASRT United States
- IMMX United States
- Employees
- ASRT N/A
- IMMX N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- ASRT Health Care
- IMMX Health Care
- Exchange
- ASRT Nasdaq
- IMMX Nasdaq
- Market Cap
- ASRT 79.1M
- IMMX 82.6M
- IPO Year
- ASRT 1997
- IMMX 2021
- Fundamental
- Price
- ASRT $0.82
- IMMX $3.58
- Analyst Decision
- ASRT Strong Buy
- IMMX Strong Buy
- Analyst Count
- ASRT 1
- IMMX 1
- Target Price
- ASRT $3.00
- IMMX $8.00
- AVG Volume (30 Days)
- ASRT 196.5K
- IMMX 667.2K
- Earning Date
- ASRT 11-10-2025
- IMMX 11-11-2025
- Dividend Yield
- ASRT N/A
- IMMX N/A
- EPS Growth
- ASRT N/A
- IMMX N/A
- EPS
- ASRT N/A
- IMMX N/A
- Revenue
- ASRT $117,099,000.00
- IMMX N/A
- Revenue This Year
- ASRT N/A
- IMMX N/A
- Revenue Next Year
- ASRT $4.10
- IMMX N/A
- P/E Ratio
- ASRT N/A
- IMMX N/A
- Revenue Growth
- ASRT N/A
- IMMX N/A
- 52 Week Low
- ASRT $0.51
- IMMX $1.34
- 52 Week High
- ASRT $1.12
- IMMX $3.66
- Technical
- Relative Strength Index (RSI)
- ASRT 44.03
- IMMX 82.18
- Support Level
- ASRT $0.81
- IMMX $2.31
- Resistance Level
- ASRT $0.85
- IMMX $2.82
- Average True Range (ATR)
- ASRT 0.04
- IMMX 0.31
- MACD
- ASRT -0.01
- IMMX 0.11
- Stochastic Oscillator
- ASRT 28.16
- IMMX 91.43
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.